DARZALEX is a Intravenous Injection, Solution, Concentrate in the Human Prescription Drug category. It is labeled and distributed by Janssen Biotech, Inc.. The primary component is Daratumumab.
Product ID | 57894-502_01d20c9e-ad31-481b-a70d-4a488353beba |
NDC | 57894-502 |
Product Type | Human Prescription Drug |
Proprietary Name | DARZALEX |
Generic Name | Daratumumab |
Dosage Form | Injection, Solution, Concentrate |
Route of Administration | INTRAVENOUS |
Marketing Start Date | 2015-11-16 |
Marketing Category | BLA / BLA |
Application Number | BLA761036 |
Labeler Name | Janssen Biotech, Inc. |
Substance Name | DARATUMUMAB |
Active Ingredient Strength | 100 mg/5mL |
Pharm Classes | CD38-directed Cytolytic Antibody [EPC],CD38-directed Antibody Interactions [MoA],Antibodies, Monoclonal [CS] |
NDC Exclude Flag | N |
Listing Certified Through | 2021-12-31 |
Marketing Start Date | 2015-11-16 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | BLA |
Application Number | BLA761036 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | ML |
Marketing Start Date | 2015-11-16 |
Marketing Category | BLA |
Application Number | BLA761036 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | ML |
Marketing Start Date | 2015-11-16 |
Ingredient | Strength |
---|---|
DARATUMUMAB | 100 mg/5mL |
SPL SET ID: | a4d0efe9-5e54-467e-9eb4-56fa7d53b60b |
Manufacturer | |
UNII | |
RxNorm Concept Unique ID - RxCUI | |
UPC Code |
NDC | Brand Name | Generic Name |
---|---|---|
57894-502 | DARZALEX | Daratumumab |
57894-505 | Darzalex IV | Daratumumab |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
DARZALEX 86354635 4933235 Live/Registered |
JOHNSON & JOHNSON 2014-08-01 |